CD19 γ-TRuC

CD19 γ-TRuC is a synthetic T cell receptor fusion construct (TRuC) developed by TCR2 Therapeutics for the treatment of B-cell malignancies. It consists of a murine anti-human CD19 single-chain variable fragment (scFv), specifically the FMC63 clone, fused via a flexible linker to the extracellular N-terminus of the CD3γ subunit of the T-cell receptor (TCR) complex. Unlike traditional chimeric antigen receptors (CARs) that rely on isolated CD3ζ signaling and exogenous co-stimulatory domains, TRuCs integrate directly into the endogenous TCR complex. This integration allows the engineered T cells to harness the full signaling potential and regulatory mechanisms of the entire TCR machinery. Preclinical data demonstrate that γ-TRuC-T cells provide potent, HLA-independent cytotoxicity against CD19-positive leukemia and lymphoma cells with a more physiological signaling profile and lower cytokine release compared to second-generation CAR-T cells.

Other names

CD19-specific γ-TRuCgamma-TRuCCD19 gamma-TRuCCD-19 gamma-TRuCCD 19 gamma-TRuC